ArticleLeukemia2017
Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.American journal of hematology · 2019Trial
- Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis.Leukemia · 2026Article
- An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies.Clinical and experimental medicine · 2026Review
- Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.Leukemia · 2026Article
- Review
- Epigenetic Modeling of Jumping Translocations of 1q Heterochromatin in Acute Myeloid Leukemia After 5'-Azacytidine Treatment.Genes, chromosomes & cancer · 2024Article
- Article
- Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm.Genetics in medicine open · 2023Article
- Cytogenetic Abnormalities in Multiple Myeloma: Incidence, Prognostic Significance, and Geographic Heterogeneity in Indian and Western Populations.Cytogenetic and genome research · 2022Article
- Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM.Blood advances · 2021Article
- [Clinical characteristics of patients with multiple myeloma harboring 6q deletion].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis.International journal of molecular sciences · 2021Review
- Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.Nature medicine · 2021Article
- Review
- Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.Oncology research and treatment · 2021Review
- Genetic Predictors of Mortality in Patients with Multiple Myeloma.The application of clinical genetics · 2021Review
- Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?Frontiers in oncology · 2020Review
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.Blood cancer journal · 2019Article
- Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.Blood cancer journal · 2019Article
- Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation ofOncotarget · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
Hyperhaploid clones (24-34 chromosomes) were identified in 33 patients with multiple myeloma (MM), demonstrating a novel numerical cytogenetic subgroup. Strikingly, all hyperhaploid karyotypes were found to harbor monosomy 17p, the single most important risk stratification lesion in MM. A catastrophic loss of nearly a haploid set of chromosomes results in disomies of chromosomes 3, 5, 7, 9, 11, 15, 18, 19 and 21, the same basic set of odd-numbered chromosomes found in trisomy in hyperdiploid myeloma. All other autosomes are found in monosomy, resulting in additional clinically relevant monosomies of 1p, 6q, 13q and 16q. Hypotriploid subclones (58-68 chromosomes) were also identified in 11 of the 33 patients and represent a duplication of the hyperhaploid clone. Analysis of clones utilizing interphase fluorescence in situ hybridization (iFISH), metaphase FISH and spectral karyotyping identified either monosomy 17 or del17p in all patients. Amplification of 1q21 was identified in eight patients, demonstrating an additional high-risk marker. Importantly, our findings indicate that current iFISH strategies may be uninformative or ambiguous in the detection of these clones, suggesting this patient subgroup maybe underreported. Overall survival for patients with hyperhaploid clones was poor, with a 5-year survival rate of 23.1%. These findings identify a distinct numerical subgroup with cytogenetically defined high-risk disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.